Protein-altering MYH3 variants are associated with a spectrum of locarpotarsal synostosis syndromephenotypes extending to spondylocarpotarsal synostosis syndrome
EUROPEAN JOURNAL OF HUMAN GENETICS
Authors: Carapito, Raphael; Goldenberg, Alice; Paul, Nicodeme; Pichot, Angelique; David, Albert; Hamel, Antoine; Dumant-Forest, Clementine; Leroux, Julien; Ory, Benjamin; Isidor, Bertrand; Bahram, Seiamak
Abstract
Spondylocarpotarsal synostosis syndrome (SCT) is a rare Mendelian disorder (OMIM # 272460) characterized by prenatal vertebral fusion, scoliosis, short stature and carpal and tarsal synostosis. SCT is typically known as an autosomal recessive disease caused by variants in the FLNB gene. The genetic basis of the rarer cases of vertical transmissions remains unknown. In two independent families with symptoms related to autosomal dominant SCT, we identified - by exome sequencing - two protein-altering variants in the embryonic myosin heavy chain 3 (MYH3) gene. As MYH3 variants are also associated with distal arthrogryposis (DA1, DA2A, DA2B) and autosomal dominant multiple pterygium syndromes (MPS), the present study expands the phenotypic spectrum of MYH3 variants to autosomal dominant SCT. Vertebral, carpal and tarsal fusions observed in both families further confirm that MYH3 plays a key role in skeletal development.
Identification of filamin C as a new, physiological substrate of PKB alpha using KESTREL
BIOCHEMICAL JOURNAL
Authors: Murray, JT; Campbell, DG; Peggie, M; Alfonso, M; Cohen, P
Abstract
We detected a protein in rabbit skeletal muscle extracts that was phosphorylated rapidly by PKBalpha (protein kinase Balpha), but not by SGK1 (serum- and glucocorticoid-induced kinase 1), and identified it as the cytoskeletal protein FLNc (filamin C). PKBalpha phosphorylated FLNc at Ser(2213) in vitro, which ties in an insert not present in the FLNa and FLNb isoforms. Ser(2213) became phosphorylated when C2C12 myoblasts were stimulated with insulin or epidermal growth factor, and phosphorylation was prevented by low concentrations of wortmannin, at which it is a relatively specific inhibitor of phosphoinositide 3-kinase. PD 184352 [an inhibitor of the classical MAPK (mitogen-activated protein kinase) cascade] and/or raparmycin [an inhibitor of mTOR (mammalian target of rapamycin)] had no effect. Insulin also induced the phosphorylation of FLNc at Ser(2213) in cardiac muscle in vivo, but not in cardiac muscle that does not express PDK1 (3-phosphoinositide-dependent kinase 1), the upstream activator of PKB. These results identify the muscle-specific isoform FLNc as a new physiological substrate for PKB.